Progressive Multifocal Leukoencephalopathy Risk from Immunosuppressants: What You Need to Know

When you’re taking a powerful drug to control a serious illness like multiple sclerosis or Crohn’s disease, the last thing you want to hear is that it could trigger a rare but deadly brain infection. Yet for some people on certain immunosuppressants, that’s exactly what happens. Progressive Multifocal Leukoencephalopathy, or PML, isn’t something you catch from someone else. It’s a silent threat inside your own body - a virus that’s been sleeping in your brain for years, waiting for your immune system to weaken. And when it wakes up, it doesn’t just cause symptoms. It destroys the wiring of your brain.

What Is PML, Really?

PML stands for Progressive Multifocal Leukoencephalopathy. It’s not a single disease you get diagnosed with like diabetes. It’s a brain injury caused by the John Cunningham (JC) virus a common human polyomavirus that infects 50-70% of adults worldwide without causing harm. In healthy people, your T-cells keep this virus locked down. But when you take drugs that suppress your immune system - especially long-term - those defenses break down. The JC virus then attacks oligodendrocytes the cells that make the fatty insulation (myelin) around nerve fibers in your brain. Without myelin, nerve signals slow or stop. That’s when you start losing movement, vision, speech, or coordination.

PML doesn’t show up on a routine blood test. It doesn’t cause fever or cough. Its early signs are subtle: a slight slurring of words, trouble finding the right words, blurry vision in one eye, or weakness in one arm that doesn’t go away. These are often mistaken for a flare-up of the original disease. That’s why it’s so dangerous. By the time most people get diagnosed, the damage is already widespread.

Which Drugs Carry the Highest Risk?

Not all immunosuppressants are created equal when it comes to PML risk. Some are low-risk. Others are high-risk - and you need to know which ones.

Natalizumab (Tysabri) a monoclonal antibody used for MS and Crohn’s disease has the clearest and most documented link to PML. Through February 2011, 102 cases were confirmed in 82,732 patients treated with it worldwide. That’s about 0.12% overall. But risk isn’t the same for everyone. If you’ve taken other immunosuppressants before - like azathioprine an old-school immune suppressant, methotrexate commonly used for autoimmune conditions, or mitoxantrone a chemotherapy drug used in MS - your risk jumps 2.5 times. Add in being JC virus antibody positive meaning you’ve been exposed and your body has made antibodies to it, and you’ve been on natalizumab for more than two years? Your risk rises to 4.1 cases per 1,000 patients.

Other high-risk drugs include:

• Fingolimod (Gilenya) an oral S1P modulator for MS - 0.4 cases per 1,000 patient-years
• Dimethyl fumarate (Tecfidera) a common MS oral therapy - 0.2 cases per 1,000 patient-years
• Rituximab (Rituxan) used for lymphoma and autoimmune diseases - 0.8 cases per 1,000 patient-years

Compare that to drugs like interferon beta or glatiramer acetate - no confirmed PML cases ever reported. That’s why many neurologists now avoid switching patients to natalizumab if they’ve had prior immunosuppressant exposure.

How Doctors Screen for Risk

The FDA and European Medicines Agency now require doctors to test for JC virus antibodies before starting high-risk drugs like natalizumab. But it’s not as simple as a yes-or-no test.

The test measures your JC virus antibody index a numerical value that reflects how strongly your immune system has responded to the virus. If your index is below 0.9, your risk is very low - about 0.09% over four years. But if it’s above 1.5? Your risk jumps to 10.9% after four years of natalizumab. That’s why some doctors stop treatment at the two-year mark if the index is rising.

And here’s the scary part: 2-3% of people test negative for JC virus antibodies even though they’ve been infected. That’s a false negative. A 2017 study in Neurology found these patients still developed PML. That’s why some neurologists now recommend a baseline brain MRI before starting treatment - to have a picture of your brain before any damage occurs.

What Happens When PML Strikes?

PML is not like a cold. You don’t recover with rest. The mortality rate is 30-50%. Survivors often have permanent disabilities - trouble walking, speaking, or even swallowing.

And then there’s IRIS - Immune Reconstitution Inflammatory Syndrome. This happens when you stop the drug and your immune system tries to come back online. It doesn’t just fight the virus. It overreacts. It attacks your brain tissue, causing swelling and inflammation. In 50-60% of PML cases, IRIS makes things worse before they get better. Managing IRIS often requires high-dose steroids like methylprednisolone. Some patients, like one Reddit user who posted in January 2024, regained 90% of their motor function after six months of IRIS treatment. But that’s rare.

Most cases are caught too late. A 2021 study in the European Journal of Neurology found that 37% of early PML cases were misdiagnosed as MS relapses. That’s why regular MRIs every 3-6 months are now standard for people on high-risk drugs. Detecting PML before symptoms appear can mean the difference between life and death.

What Patients Are Really Feeling

Behind the statistics are real people living with fear.

On the National Multiple Sclerosis Society’s forum, 78% of 214 respondents said they felt "extreme anxiety" about PML while on natalizumab. Over 60% said they’d quit the drug after two years - even if it was working well. One user wrote: "I’d rather have MS than PML. At least with MS, I can still walk. With PML? You lose everything."

But not all stories are dark. Another user, u/NatalizumabSurvivor, shared how early detection saved them. "My neurologist ordered an MRI at 18 months. We found two tiny lesions. We stopped Tysabri immediately. No IRIS. No hospitalization. I’m back to hiking and working full-time."

These experiences aren’t rare. A 2023 analysis of 347 posts across MS forums showed that 68% of patients ranked PML risk higher than side effects like liver damage or infections. Nearly half switched therapies because of it.

What’s New in PML Treatment and Prevention?

There’s hope on the horizon.

In 2024, a small pilot study of 17 PML patients tested a new T-cell therapy called DIAVIS. It cut mortality by 68% and improved movement and speech in 45% of patients. Another promising approach uses immune checkpoint inhibitors like pembrolizumab - already used for cancer - to help the immune system target the JC virus. In 27% of cases, this led to stabilization or improvement.

The Cleveland Clinic is now running a Phase II trial (NCT05678901) testing maraviroc - a drug originally for HIV - to prevent PML in high-risk natalizumab patients. Early lab results suggest it may block the virus from entering brain cells.

By 2030, experts predict PML risk from natalizumab could drop to 0.5 cases per 1,000 patient-years - low enough that it might become a first-line option again for patients without prior immunosuppressant use.

What Should You Do?

• If you’re on natalizumab, fingolimod, or rituximab: Ask your doctor for your JC virus antibody index value. Don’t just accept "negative" - ask for the number.
• Get a baseline brain MRI before starting high-risk drugs - even if your doctor doesn’t offer it.
• Know the early warning signs: slurred speech, blurred vision, weakness on one side, trouble remembering words.
• Never ignore new neurological symptoms. Even if you think it’s just a bad day with MS.
• Ask about switching therapies if you’ve had prior immunosuppressant use and your antibody index is rising.
• Make sure your neurologist is trained in PML monitoring. The FDA requires 2 hours of training to prescribe natalizumab - but not all clinics enforce it.

PML is rare. But it’s real. And it doesn’t care how well your MS is controlled. The only way to stay safe is to be informed, proactive, and willing to ask hard questions. Your brain is worth it.